1. Scrip
  2. >>Business
  3. >>Financing
  4. >>Finance Watch

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

Third Harmonic Provides Update On Liquidation

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Finance Watch Public Company
• Source: Alamy

Insmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its stock price 29% higher to $90.93 on June 10, with a super-sized follow-on public offering (FOPO) one day later. The company grossed $750m from the sale of 7.81 million shares at $96 each.

The offering follows 13 months after Insmed’s last big post-data FOPO, an offering of 12.62 million shares at $51.50 that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Finance Watch

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.